Show simple item record

dc.contributor.authorKim, Byeong-Keuk
dc.contributor.authorDalal, Jamshed
dc.contributor.authorTam, Li-Wah
dc.contributor.authorSteg, Gabriel
dc.contributor.authorNguyen, Quang N.
dc.contributor.authorAko, Junya
dc.contributor.authorAl Suwaidi, Jassim
dc.contributor.authorChan, Mark
dc.contributor.authorSobhy, Mohamed
dc.contributor.authorShehab, Abdulla
dc.contributor.authorBuddhari, Wacin
dc.contributor.authorWang, Zulu
dc.contributor.authorFong, Alan Yean Yip
dc.contributor.authorKaradag, Bilgehan
dc.contributor.authorAlmahmeed, Wael
dc.contributor.authorBaber, Usman
dc.contributor.authorChin, Chee Tang
dc.contributor.authorHan, Ya Ling
dc.contributor.authorTan, Jack Wei Chieh
dc.contributor.authorChew, Derek P.
dc.contributor.authorTsui, Kin Lam
dc.contributor.authorTan, Doreen
dc.contributor.authorDuplyakov, Dmitry
dc.contributor.authorHammoudeh, Ayman
dc.contributor.authorZhang, Bo
dc.contributor.authorLi, Yi
dc.contributor.authorXu, Kai
dc.contributor.authorOng, Paul J.
dc.contributor.authorFirman, Doni
dc.contributor.authorGamra, Habib
dc.date.accessioned2021-12-10T12:00:48Z
dc.date.available2021-12-10T12:00:48Z
dc.identifier.citationTan J. W. C. , Chew D. P. , Tsui K. L. , Tan D., Duplyakov D., Hammoudeh A., Zhang B., Li Y., Xu K., Ong P. J. , et al., "2021 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y(12) Receptor Antagonists in the Asia-Pacific Region: Special Populations", EUROPEAN CARDIOLOGY REVIEW, cilt.16, 2021
dc.identifier.otherav_a32c8f72-2a4b-474c-bb75-58eaac820c8e
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/173079
dc.identifier.urihttps://doi.org/10.15420/ecr.2021.35
dc.description.abstractAdvanced age, diabetes, and chronic kidney disease not only increase the risk for ischaemic events in chronic coronary syndromes (CCS) but also confer a high bleeding risk during antiplatelet therapy. These special populations may warrant modification of therapy, especially among Asians, who have displayed characteristics that are clinically distinct from Western patients. Previous guidance has been provided regarding the classification of high-risk CCS and the use of newer-generation P2Y(12) inhibitors (i.e. ticagrelor and prasugrel) after acute coronary syndromes (ACS) in Asia. The authors summarise evidence on the use of these P2Y(12) inhibitors during the transition from ACS to CCS and among special populations. Specifically, they present recommendations on the roles of standard dual antiplatelet therapy, shortened dual antiplatelet therapy and single antiplatelet therapy among patients with coronary artery disease, who are either transitioning from ACS to CCS; elderly; or with chronic kidney disease, diabetes, multivessel coronary artery disease and bleeding events during therapy.
dc.language.isoeng
dc.subjectKardiyoloji
dc.subjectCardiology and Cardiovascular Medicine
dc.subjectHealth Sciences
dc.subjectCARDIAC ve CARDIOVASCULAR SİSTEMLER
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.title2021 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y(12) Receptor Antagonists in the Asia-Pacific Region: Special Populations
dc.typeMakale
dc.relation.journalEUROPEAN CARDIOLOGY REVIEW
dc.contributor.departmentNatl Heart Ctr , ,
dc.identifier.volume16
dc.contributor.firstauthorID2769834


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record